NGM Biopharmaceuticals (NGM) Stock Forecast, Price Target & Predictions
NGM Stock Forecast
NGM Biopharmaceuticals stock forecast is as follows: an average price target of $16.50 (represents a 971.43% upside from NGM’s last price of $1.54) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NGM Price Target
The average price target for NGM Biopharmaceuticals (NGM) is $16.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $4.00. This represents a potential 971.43% upside from NGM's last price of $1.54.
NGM Analyst Ratings
According to 4 Wall Street analysts, NGM Biopharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for NGM stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
NGM Biopharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2022 | Steven Seedhouse | Raymond James | - | - | 17.30% | 159.74% |
| May 24, 2022 | Goldman Sachs | - | - | 112.61% | 1783.12% |
The latest NGM Biopharmaceuticals stock forecast, released on Oct 17, 2022 by Steven Seedhouse from Raymond James, set a price target of $4.00, which represents a 17.30% increase from the stock price at the time of the forecast ($3.41), and a 159.74% increase from NGM last price ($1.54).
NGM Biopharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.54 | $1.54 | $1.54 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of NGM Biopharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NGM Biopharmaceuticals's last price of $1.54. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 22, 2023 | B. Riley Securities | Buy | Buy | Hold |
| Oct 17, 2022 | Raymond James | Outperform | Downgrade | |
| Oct 17, 2022 | Piper Sandler | Neutral | Downgrade | |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
NGM Biopharmaceuticals's last stock rating was published by B. Riley Securities on Nov 22, 2023. The company gave NGM a "Buy" rating, the same as its previous rate.
NGM Biopharmaceuticals Financial Forecast
NGM Biopharmaceuticals Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $2.25M | $18.18M | $7.91M | $8.29M | $20.95M | - | $18.57M | $16.77M | $21.57M | $19.77M | $23.48M | $19.75M | $24.36M | $31.08M | $21.57M | $25.34M | $25.55M |
| Avg Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| High Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| Low Forecast | $104.18K | $31.43K | $52.38K | $87.30K | $558.20K | $2.46M | $3.30M | $6.14M | $6.77M | $7.06M | $13.40M | $14.95M | $20.20M | $22.65M | $22.55M | $22.49M | $21.97M | $20.45M | $21.78M | $23.19M | $17.07M | $17.87M | $21.69M | $21.59M |
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.37% | 2.69% | 1.12% | 0.62% | 1.40% | - | 0.82% | 0.74% | 0.96% | 0.90% | 1.15% | 0.91% | 1.05% | 1.82% | 1.21% | 1.17% | 1.18% |
NGM Biopharmaceuticals's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.30M, with a low forecast of $3.30M, and a high forecast of $3.30M. NGM's average Quarter revenue forecast represents a 47.05% increase compared to the company's last Quarter revenue of $2.25M (Mar 23).
NGM Biopharmaceuticals EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | $-31.03M | $-40.58M | $-50.19M | $-38.30M | $-47.71M | $-45.67M | $-31.15M | $-25.75M | $-27.37M | $-35.13M | $-25.99M | $-26.44M | $-28.14M | $-23.97M | $-17.38M | $-14.17M | $-8.97M | $-5.73M | $-6.31M |
| Avg Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-33.53M | $-18.08M | $-20.28M | $-20.19M | $-29.70M | $-19.67M | $-18.30M | $-19.50M | $-16.74M | $-15.28M | $-16.00M | $-19.42M | $-13.18M |
| High Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-26.82M | $-18.08M | $-20.28M | $-20.19M | $-23.76M | $-19.67M | $-18.30M | $-19.50M | $-13.39M | $-15.28M | $-16.00M | $-19.42M | $-10.54M |
| Low Forecast | $-93.27K | $-28.14K | $-46.90K | $-78.16K | $-499.76K | $-2.20M | $-2.96M | $-5.49M | $-6.06M | $-6.32M | $-12.00M | $-40.24M | $-18.08M | $-20.28M | $-20.19M | $-35.64M | $-19.67M | $-18.30M | $-19.50M | $-20.09M | $-15.28M | $-16.00M | $-19.42M | $-15.81M |
| Surprise % | - | - | - | - | - | 14.12% | 13.72% | 9.14% | 6.32% | 7.54% | 3.81% | 0.93% | 1.42% | 1.35% | 1.74% | 0.88% | 1.34% | 1.54% | 1.23% | 1.04% | 0.93% | 0.56% | 0.30% | 0.48% |
undefined analysts predict NGM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NGM Biopharmaceuticals's previous annual EBITDA (undefined) of $NaN.
NGM Biopharmaceuticals Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | $-28.80M | $-38.26M | $-45.10M | $-34.58M | $-46.22M | $-45.97M | $-32.32M | - | $-28.86M | $-36.69M | $-27.54M | $-27.99M | $-29.77M | $-25.62M | $-19.11M | $-15.94M | $-10.92M | $-7.67M | $-8.27M |
| Avg Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-32.56M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-35.27M | $-29.81M | $-27.74M | $-28.74M | $-31.48M | $-38.45M | $-30.34M | $-25.37M | $-18.41M | $-21.88M | $-22.87M | $-69.11M | $-17.27M |
| High Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-27.28M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-28.22M | $-29.81M | $-27.74M | $-28.74M | $-25.18M | $-38.45M | $-30.34M | $-25.37M | $-14.73M | $-21.88M | $-22.87M | $-69.11M | $-13.82M |
| Low Forecast | $-15.73M | $-26.60M | $-28.15M | $-34.29M | $-44.00M | $-35.13M | $-41.22M | $-42.82M | $-42.64M | $-48.99M | $-44.02M | $-42.33M | $-29.81M | $-27.74M | $-28.74M | $-37.77M | $-38.45M | $-30.34M | $-25.37M | $-22.09M | $-21.88M | $-22.87M | $-69.11M | $-20.73M |
| Surprise % | - | - | - | - | - | 0.82% | 0.93% | 1.05% | 0.81% | 0.94% | 1.04% | 0.92% | - | 1.04% | 1.28% | 0.88% | 0.73% | 0.98% | 1.01% | 1.04% | 0.73% | 0.48% | 0.11% | 0.48% |
NGM Biopharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NGM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NGM Biopharmaceuticals SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | $8.67M | $9.65M | $11.58M | $9.76M | $10.11M | $9.93M | $10.72M | - | $8.87M | $9.82M | $8.72M | $7.38M | $6.46M | $6.79M | $6.59M | $6.42M | $5.61M | $6.23M | $5.37M |
| Avg Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $11.66M | $40.64M | $45.59M | $45.39M | $9.97M | $44.21M | $41.14M | $43.84M | $6.35M | $34.34M | $35.96M | $43.64M | $11.21M |
| High Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $13.99M | $40.64M | $45.59M | $45.39M | $11.96M | $44.21M | $41.14M | $43.84M | $7.62M | $34.34M | $35.96M | $43.64M | $13.46M |
| Low Forecast | $209.65K | $63.24K | $105.41K | $175.69K | $1.12M | $4.94M | $6.65M | $12.35M | $13.62M | $14.22M | $26.97M | $9.32M | $40.64M | $45.59M | $45.39M | $7.97M | $44.21M | $41.14M | $43.84M | $5.08M | $34.34M | $35.96M | $43.64M | $8.97M |
| Surprise % | - | - | - | - | - | 1.75% | 1.45% | 0.94% | 0.72% | 0.71% | 0.37% | 0.92% | - | 0.19% | 0.22% | 0.88% | 0.17% | 0.16% | 0.15% | 1.04% | 0.19% | 0.16% | 0.14% | 0.48% |
NGM Biopharmaceuticals's average Quarter SG&A projection for Dec 23 is $1.12M, based on 3 Wall Street analysts, with a range of $1.12M to $1.12M. The forecast indicates a -87.04% fall compared to NGM last annual SG&A of $8.67M (Sep 23).
NGM Biopharmaceuticals EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | $-0.35 | $-0.46 | $-0.55 | $-0.42 | $-0.57 | $-0.58 | $-0.41 | - | $-0.37 | $-0.48 | $-0.36 | $-0.40 | $-0.43 | $-0.38 | $-0.28 | $-0.24 | $-0.17 | $-0.13 | $-0.13 |
| Avg Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.39 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| High Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.33 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| Low Forecast | $-0.19 | $-0.32 | $-0.34 | $-0.41 | $-0.53 | $-0.42 | $-0.50 | $-0.52 | $-0.52 | $-0.59 | $-0.53 | $-0.46 | $-0.36 | $-0.34 | $-0.35 | $-0.41 | $-0.46 | $-0.37 | $-0.31 | $-0.28 | $-0.26 | $-0.28 | $-0.83 | $-0.28 |
| Surprise % | - | - | - | - | - | 0.82% | 0.92% | 1.06% | 0.82% | 0.96% | 1.09% | 0.90% | - | 1.10% | 1.38% | 0.88% | 0.86% | 1.17% | 1.24% | 0.99% | 0.91% | 0.62% | 0.16% | 0.46% |
According to undefined Wall Street analysts, NGM Biopharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NGM previous annual EPS of $NaN (undefined).
NGM Biopharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | - | - | 1139.67% | Buy |
| NGM | NGM Biopharmaceuticals | - | - | 971.43% | Buy |
| NKTX | Nkarta | - | - | 781.63% | Buy |
| LYEL | Lyell Immunopharma | - | - | 602.11% | Hold |
| PRLD | Prelude Therapeutics | - | - | 557.89% | Sell |
| CCCC | C4 Therapeutics | - | - | 217.65% | Buy |
| SANA | Sana Bio | - | - | 206.51% | Buy |
| TIL | Instil Bio | - | - | 199.24% | Hold |
| RZLT | Rezolute | - | - | 174.95% | Buy |
| NXTC | NextCure | - | - | 152.10% | Buy |
| ERAS | Erasca | - | - | 140.74% | Buy |
| MLYS | Mineralys Therapeutics | - | - | 140.19% | Buy |
| ASMB | Assembly Biosciences | - | - | 136.04% | Buy |
| KZR | Kezar Life Sciences | - | - | 133.33% | Buy |
| FHTX | Foghorn Therapeutics | - | - | 108.29% | Buy |
| ACHL | Achilles Therapeutics | - | - | 88.68% | Buy |
| KROS | Keros Therapeutics | - | - | 83.48% | Buy |
| CYT | Cyteir Therapeutics | - | - | -33.77% | Sell |